N+1 Singer shares its Q1 2018 Review

In our Q1 2018 review, we discuss the UK  economic and equity market environment and notable transactions completed in the first quarter of 2018.

[Video] Elektron Techology – Hidden value

Please click on the video to hear Jo Reedman talk about Elektron Technology’s three businesses: Bulgin, Elektron Eye Technology and Checkit. She discusses the group’s strong FY18 results and encouraging start to FY19, management’s plans to

Read More
FreeAgent acquired by RBS for £53 million

RBS has announced its intention to acquire our client FreeAgent for £53m. This is the first time since the 2008 crisis that RBS acquires a business. Quoted on AIM since November 2016 FreeAgent is a provider

Read More
Summit Therapeutics raises £15.0m

Summit Therapeutics plc, the Oxford based drug discovery and development company advancing therapies for rare and infectious diseases, announced today that it has raised £15 million. The Placing, which was oversubscribed, was conducted by means of

Read More
2018 Extel survey

We at N+1 Singer are very proud of our Research output and we’ve listed below some of our achievements. We are grateful for the ongoing support of our institutional clients in internal and external surveys and

Read More
[Video] Pharmaceutical Services – Structural growth in a complex landscape

Please click on the video below to hear our analysts present the main themes of their latest Pharmaceutical Services sector report.    To receive the full sector note, email enquiry@n1singer.com

Read More
Theresa May’s Housing Speech and (overblown) Help to Buy concerns

The weekend saw a flurry of press articles describing the onset of Help to Buy interest payments as a “ticking time bomb”, rhetoric which we consider to be overblown. This was followed by yesterday’s housing speech

Read More

Transaction Highlights

FreeAgent

Date: Mar 2018

Sector: Technology 

Type: M&A advisory


£35.0 million

Summit Therapeutics

Date: Mar 2018

Sector: Life sciences

Type: Placing


£15.0 million

The PRS REIT

Date: Feb 2018

Sector: Investment Funds

Type: Placing


£250.0 million

Communications about our events, transactions  and trends shaping industries.